• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Idorsia Pharmaceuticals Reveals Support for Department of Defense Clinical Trials


Government sponsored study to test effectiveness of Quviviq in those living with PTSD.

asian man in bed suffering insomnia and sleep disorder thinking about his problem at night. Image Credit: Adobe Stock Images/princeoflove

Idorsia Pharmaceuticals, a biopharmaceutical company, is officially supporting a Department of Defense (DOD) study focusing on the development of new therapies to treat posttraumatic stress disorder (PTSD). As a part of the clinical trial, insomnia medication Quviviq will be included along with two other FDA-approved depression treatments. Together, these medicines will be studied under an investigational new drug application.

Expected to enroll its first test subjects in Q2 of this year, Quviviq will be involved for an estimated three years.

"This innovative clinical trial and public-private partnership addresses the need for safe and effective therapies to treat PTSD in our current and former servicemen and women, as well as the general population," said Dr. Kimberly del Carmen, the DOD's PTSD drug treatment program product manager. "We'll efficiently test multiple potential treatments for PTSD and significantly contribute to the development of new safe and effective therapies."

Reference: Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD). May 10, 2023/PR Newswire

Related Videos